Literature DB >> 6222069

Protection of factor Xa from neutralization by the heparin-antithrombin complex.

J M Teitel, R D Rosenberg.   

Abstract

We have studied the accessibility of Factor Xa to neutralization by the heparin-antithrombin complex within plasma and whole blood. This serine protease was detected by measuring the concentrations of activation fragments (F2/F1+2) cleaved from prothrombin. The levels of F2/F1+2) were quantitated by means of a sensitive and specific radioimmunoassay. Our findings indicate that the binding of Factor Xa to "activated" platelets but not to phospholipid micelles results in the protection of the above enzyme from inactivation by the heparin-antithrombin complex. This sequestration of Factor Xa is not affected by the liberation of platelet release proteins or the molecular heterogeneity of the mucopolysaccharide preparations used. The magnitude of enzyme protection is strongly correlated with the extent of prothrombin activation at the time of heparin addition. On this basis, we suggest that high in vivo rates of thrombin generation may lead to the sequestration of Factor Xa on the platelet surface and hence allow this serine protease to resist the action of heparin until the complex is cleared from the circulation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6222069      PMCID: PMC437002          DOI: 10.1172/jci110891

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Studies on fractionated heparin.

Authors:  T C LAURENT
Journal:  Arch Biochem Biophys       Date:  1961-02       Impact factor: 4.013

2.  Statistical characterization of the random errors in the radioimmunoassay dose--response variable.

Authors:  D Rodbard; R H Lenox; H L Wray; D Ramseth
Journal:  Clin Chem       Date:  1976-03       Impact factor: 8.327

3.  The separation of active and inactive forms of heparin.

Authors:  L H Lam; J E Silbert; R D Rosenberg
Journal:  Biochem Biophys Res Commun       Date:  1976-03-22       Impact factor: 3.575

Review 4.  Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays.

Authors:  D Rodbard
Journal:  Clin Chem       Date:  1974-10       Impact factor: 8.327

5.  A plausible mechanism for prothrombin activation by factor Xa, factor Va, phospholipid, and calcium ions.

Authors:  C T Esmon; W G Owen; C M Jackson
Journal:  J Biol Chem       Date:  1974-12-25       Impact factor: 5.157

6.  Effect of heparin on the neutralization of factor Xa and thrombin by the plasma alpha-2-globulin inhibitor.

Authors:  E T Yin
Journal:  Thromb Diath Haemorrh       Date:  1975-02-28

7.  Factor-Xa inactivation by antithrombin. 3. Evidence for biological stabilization of factor Xa by factor V-phospholipid complex.

Authors:  E Marciniak
Journal:  Br J Haematol       Date:  1973-03       Impact factor: 6.998

8.  Relationship between platelet secretion and prothrombin cleavage in native whole blood.

Authors:  M E Rybak; H K Lau; B Tomkins; R D Rosenberg; R I Handin
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

9.  Heparin with two binding sites for antithrombin or platelet factor 4.

Authors:  R E Jordan; L V Favreau; E H Braswell; R D Rosenberg
Journal:  J Biol Chem       Date:  1982-01-10       Impact factor: 5.157

10.  Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex.

Authors:  J M Teitel; K A Bauer; H K Lau; R D Rosenberg
Journal:  Blood       Date:  1982-05       Impact factor: 22.113

View more
  17 in total

Review 1.  New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice.

Authors:  R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

3.  Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

4.  Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

5.  Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.

Authors:  Ivan Stevic; Howard H W Chan; Leslie R Berry; Ankush Chander; Anthony K C Chan
Journal:  J Biochem       Date:  2012-10-24       Impact factor: 3.387

6.  Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor.

Authors:  J Franssen; I Salemink; G M Willems; T C Wun; H C Hemker; T Lindhout
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

Review 7.  Natural anticoagulant mechanisms.

Authors:  R D Rosenberg; J S Rosenberg
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

8.  Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.

Authors:  D J Fitzgerald; G A Fitzgerald
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

9.  Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.

Authors:  D J Fitzgerald; M Hanson; G A FitzGerald
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

10.  The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides.

Authors:  T W Barrowcliffe; S J Havercroft; G Kemball-Cook; U Lindahl
Journal:  Biochem J       Date:  1987-04-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.